Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Roberts; Michael W. Deininger; Gerhard C. Hildebrandt; Brian K. Gackenbach; Maxwell M. Krem

doi:10.1080/10428194.2020.1808210

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Roberts, Michael W. Deininger, Gerhard C. Hildebrandt, Brian K. Gackenbach, Maxwell M. Krem

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	3507-3510
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	61
Issue number	14
DOIs	https://doi.org/10.1080/10428194.2020.1808210
State	Published - 2020

Bibliographical note

Funding Information:
GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Funding

GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Funders	Funder number
Incyte
National Institutes of Health (NIH)
National Childhood Cancer Registry – National Cancer Institute	R01CA178397
Astellas Pharma Inc.

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2020.1808210

Cite this

@article{920fa802d4ed47e68ca4f8002518b05e,

title = "Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia",

author = "Roberts, \{Kandice E.\} and Deininger, \{Michael W.\} and Hildebrandt, \{Gerhard C.\} and Gackenbach, \{Brian K.\} and Krem, \{Maxwell M.\}",

note = "Funding Information: GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.",

year = "2020",

doi = "10.1080/10428194.2020.1808210",

language = "English",

volume = "61",

pages = "3507--3510",

number = "14",

}

TY - JOUR

T1 - Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

AU - Roberts, Kandice E.

AU - Deininger, Michael W.

AU - Hildebrandt, Gerhard C.

AU - Gackenbach, Brian K.

AU - Krem, Maxwell M.

N1 - Funding Information: GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

PY - 2020

Y1 - 2020

UR - http://www.scopus.com/inward/record.url?scp=85089783902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089783902&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1808210

DO - 10.1080/10428194.2020.1808210

M3 - Letter

C2 - 32835547

AN - SCOPUS:85089783902

SN - 1042-8194

VL - 61

SP - 3507

EP - 3510

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 14

ER -

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this